- Home
- ENTA vs VBF Comparison
ENTA vs VBF Comparison
Compare ENTA & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- VBF
- Stock Information
- Founded
- ENTA 1995
- VBF 1970
- Country
- ENTA United States
- VBF United States
- Employees
- ENTA N/A
- VBF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- VBF Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- VBF Finance
- Exchange
- ENTA Nasdaq
- VBF Nasdaq
- Market Cap
- ENTA 164.6M
- VBF 177.1M
- IPO Year
- ENTA 2013
- VBF N/A
- Fundamental
- Price
- ENTA $11.29
- VBF $15.71
- Analyst Decision
- ENTA Strong Buy
- VBF
- Analyst Count
- ENTA 6
- VBF 0
- Target Price
- ENTA $20.83
- VBF N/A
- AVG Volume (30 Days)
- ENTA 1.5M
- VBF 45.5K
- Earning Date
- ENTA 11-24-2025
- VBF 01-01-0001
- Dividend Yield
- ENTA N/A
- VBF 5.18%
- EPS Growth
- ENTA N/A
- VBF N/A
- EPS
- ENTA N/A
- VBF N/A
- Revenue
- ENTA $64,806,000.00
- VBF N/A
- Revenue This Year
- ENTA $0.07
- VBF N/A
- Revenue Next Year
- ENTA N/A
- VBF N/A
- P/E Ratio
- ENTA N/A
- VBF N/A
- Revenue Growth
- ENTA N/A
- VBF N/A
- 52 Week Low
- ENTA $4.09
- VBF $13.68
- 52 Week High
- ENTA $15.34
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- ENTA 59.34
- VBF 49.97
- Support Level
- ENTA $9.91
- VBF $15.73
- Resistance Level
- ENTA $11.59
- VBF $15.84
- Average True Range (ATR)
- ENTA 1.52
- VBF 0.10
- MACD
- ENTA 0.19
- VBF -0.02
- Stochastic Oscillator
- ENTA 52.96
- VBF 33.09
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.